DBS starts 3SBio stock at Buy with HKD 17.80 target

Published on 10/20/2026 at 20:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 3.90 percent to RMB 4.53 billion. 3SBio stock costs EUR 1.63 on October 20, 2026 after HKD 14.47 on HKEX.

Analyst target and interim results

DBS initiated coverage with a Buy rating and an HKD 17.80 target on October 16, 2026.
First-half 2026 revenue rose 3.90 percent to RMB 4.53 billion.
3SBio stock costs EUR 1.63 at Lang & Schwarz on October 20, 2026 at 8:32 p.m. CEST.
Adjusted operating net profit increased 26.50 percent to RMB 1.44 billion in the first half of 2026.

3SBio, KYG8875G1029, Illustration mit AI erstellt.

3SBio stock (ISIN KYG8875G1029) has an HKD 17.80 target from DBS Bank, which began coverage with a Buy rating on October 16, 2026, according to MarketScreener. The target is 21.09 percent above the HKD 14.70 last price on HKEX on October 20, 2026. At Lang & Schwarz, the stock was trading at EUR 1.63 on October 20, 2026 at 8:32 p.m. CEST.

Interim results split the picture

3SBio reported first-half 2026 revenue of RMB 4.53 billion, up 3.90 percent from the year-earlier period. The six-month report also showed net profit attributable to shareholders falling 15.60 percent to RMB 1.15 billion, while adjusted operating net profit increased 26.50 percent to RMB 1.44 billion. These figures came from the interim report published on September 30, 2026, carried by Futubull.

The margin mix also changed. Gross margin declined from 85.30 percent to 83.80 percent in the first half of 2026, while CDMO revenue rose 160.90 percent year over year to RMB 230.00 million.

What does DBS target imply?

The HKD 17.80 target stands 21.09 percent above the HKD 14.70 HKEX price on October 20, 2026. The target therefore sits above the current quotation even as the latest earnings report combines lower headline profit with higher adjusted operating profit. A September 22 analysis by First Capital Securities reported first-half revenue of RMB 4.526 billion, net profit of RMB 1.147 billion and adjusted operating profit of RMB 1.436 billion, while maintaining an Add rating, according to Futubull.

3SBio and two peers

3SBio (HKEX, HKD): up 1.59 percent on October 20, 2026, P/E 3.78, market capitalization HKD 36.8 billion.

Innovent Biologics (HKEX, HKD): down 1.85 percent on October 20, 2026, P/E 111.27, market capitalization HKD 152.4 billion.

Jiangsu Hengrui Medicine (Shanghai Stock Exchange, CNY): up 2.97 percent on October 20, 2026, P/E 40.56, market capitalization CNY 302.7 billion.

Price and trading frame

3SBio's 52-week range was HKD 14.09 to HKD 35.42 as of October 20, 2026, placing the HKD 14.70 quotation 1.41 percent above the low. Trading volume reached 14,432,232 shares on the Hong Kong Stock Exchange. The company operates in pharmaceuticals and biopharmaceutical manufacturing, including CDMO services.

3SBio was trading at EUR 1.63 at Lang & Schwarz on October 20, 2026 at 8:32 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of 3SBio stock.